NEW DELHI: Indian doctors and politicians on Thursday welcomed efficacy data for a state-backed coronavirus vaccine that was given emergency approval in January without the completion of a late-stage trial, making people reluctant to receive the shot.
Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said on Wednesday.
Any boost to the vaccine's acceptance in India, which on Thursday reported a new COVID-19 cases at their highest in five weeks, could also brighten its export prospects. Bharat Biotech said 40 countries were interested in COVAXIN.
Many Indian doctors and opposition politicians had rejected COVAXIN because it was approved by the drug regulator only on the basis of data from intermediate trials. The regulator has also authorised the use of the Oxford University/AstraZeneca vaccine, marketed as Covishield in India, which was found to be 70.42% effective based on overseas trials.
"Now that interim Phase 3 data are available for COVAXIN, I can safely ask my father, who is more than 60 years of age and a diabetic, to get it," said Nirmalya Mohapatra, a leader of an association of doctors at New Delhi's Ram Manohar Lohia Hospital, having previously publicly refused to take COVAXIN.
Rajib Dasgupta, chairperson of the Centre of Social Medicine & Community Health at New Delhi's Jawaharlal Nehru University, said the interim results were encouraging but that a "well-rounded picture" would emerge only after a fuller analysis.
Opposition lawmaker Shashi Tharoor welcomed Bharat Biotech's announcement.
"For those like me who were concerned that COVAXIN was being deployed before its third phase trials were concluded, this is good news indeed," he said on Twitter.
India reported 17,407 COVID-19 cases in the past 24 hours, taking the total to 11.16 million. Deaths rose by 89 to 157,435.
Reuters
Thu Mar 04 2021
Many Indian doctors and opposition politicians had rejected COVAXIN because it was approved by the drug regulator only on the basis of data from intermediate trials. REUTERSpic
Leftenan Muda Min Youn satu-satunya penuntut bangsa Cina tamat latihan Komando GGK 2024
Min Youn yang berasal dari Setapak, Kuala Lumpur itu merupakan graduan perakaunan daripada Universiti Tunku Abdul Rahman (UTAR).
Seorang maut, nahas dua kereta di Ipoh
Kemalangan melibatkan dua buah kereta iaitu jenis Honda City dan Peugeot.
Play Store kini benarkan muat turun dua aplikasi serentak
Berdasarkan laporan 9to5Google, ciri ini diberikan secara berperingkat kepada pengguna Android bermula dengan peranti\
Che'gu Bard mengaku tidak bersalah dua pertuduhan
Badrul Hisham mengaku tidak bersalah, selepas semua pertuduhan dibaca di hadapan Hakim, Siti Aminah Ghazali.
Tahanan PPA tekad jadikan kemahiran dalam “tirai besi” sebagai mata pencarian
Kehidupan di dalam tirai besi memberikan keinsafan kepada Fifi, Apit dan Bulat.
Ringgit susut berbanding dolar AS pada sesi awal
Pada 9 pagi, ringgit merosot kepada 4.7715/7810 berbanding mata wang Amerika Syarikat (AS) daripada 4.7650/7710 pada Jumaat.
Guna semula bangunan pawagam lama, bangkit suasana klasik
Ia bukan sahaja mampu menarik ramai pelancong tetapi juga mampu memulihara bangunan warisan yang masih elok dan ditatap oleh generasi kini.
Mesyuarat Khas WEF: PM Anwar jumpa 50 pemimpin industri, perniagaan global
PM yakin lebih banyak pelabur bernilai tinggi akan pilih Malaysia sebagai destinasi pelaburan.
Dipaksa bersalin normal, kepala bayi songsang terputus
Bahagian kemaluannya juga terkoyak teruk dan dijahit sebarangan oleh staf Rumah Sakit Banjarmasin.
AWANI Ringkas: Tangani isu ketidaksamaan & marginalisasi
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
COVID-19: WHO gantung bekalan vaksin Covaxin
Ini bagi membolehkan pengilang menaik taraf kemudahan dan menangani kekurangan yang ditemui dalam pemeriksaan.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Vaksin COVID-19: WHO belum beri kelulusan global terhadap Covaxin
Tanpa kelulusan daripada WHO, Covaxin dengan dua dos itu tidak akan diterima sebagai vaksin yang sah untuk digunakan di seluruh dunia.
Vaksin COVID-19: Covaxin buatan Bharat Biotech berkesan 93.4%
Data menunjukkan perlindungan 65.2 peratus terhadap varian Delta yang pertama kali dikesan di India dan menyebabkan lonjakan kes pada April dan Mei lalu.
Vaksin COVID-19: 40,000 dos mungkin perlu dilupus selepas pemandu tinggalkan lori
Polis menemui lori berkenaan yang membawa 364 kotak bekalan vaksin 'Covaxin' keluaran Bharat Biotech bernilai AS$1.08 juta.
Pelakon Vivek meninggal dunia akibat serangan jantung
Pelakon popular India, Vivek yang dimasukkan ke Hospital SIMS di Vadapalani selepas diserang sakit jantung, meninggal dunia pada pukul 4.35 pagi, waktu tempatan hari ini (Malaysia 7.05 pagi).